Inventory: Indications, prices, sales

This article reviews the progress in clinical applications of pluripotent stem cell (hPSC)-derived therapies around the world.

On January 7, 2025, China's first induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of Parkinson's disease made breakthrough progress at Shanghai City Dongfang Hospital.

According to data released by South Korean biotechnology company Medipost in 2024, the cumulative number of patients treated by Cartistem, its knee osteoarthritis stem cell therapy, has exceeded 30000.

On January 2, the State Food and Drug Administration conditionally approved the marketing of my country's first stem cell treatment drug, Amimetosa Injection, through the priority review and approval process.

In 2024, nearly 35 domestic iPSC companies entered the market, promoting the rapid progress of universal cell therapies.

In the vast field of medical research, human amniotic mesenchymal stem cells (hAMSC) are gradually coming into prominence.

Human body: A living body composed of approximately 40 trillion cells